Zhitong Finance App News, Zhongsheng Pharmaceutical (002317.SZ) issued an announcement. Recently, according to public information issued by the Drug Evaluation Center (CDE) of the State Drug Administration, the holding subsidiary of Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., ZSP1601 tablets, a class of innovative drugs independently developed by the company's holding subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., were included in the breakthrough therapeutic drug program by CDE. The intended indication for this drug is metabolism-related steatohepatitis (MASH).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.